ALLMedicine™ Apolipoprotein A-I Center
Research & Reviews 517 results
Metabolism: Clinical and Experimental; Daskou M, Sharma M et. al.
Sep 13th, 2021 - We investigated whether apolipoprotein A-I (apoA-I) mimetic peptides 4F and 6F can be a novel therapeutic strategy to reduce blood and gut bioactive lipids, proinflammatory effects of endotoxin (LPS) and aberrant activation of cyclooxygenase 2 (CO...
https://doi.org/10.1007/s00404-021-06215-3 10.1002/ijc.31937 10.1016/S1470-2045(13)70363-2 10.1056/NEJMoa1103799 10.1056/NEJMoa1104390 10.1056/NEJMoa052985 10.5041/RMMJ.10106 10.1097/MCO.0000000000000381 10.1038/nrc.2016.89 10.3390/cancers11121870 10.1126/science.aaw5473 10.1016/j.ccr.2012.02.014 10.1093/jnci/88.1.32 10.1016/j.clinbiochem.2007.06.007 10.18632/oncotarget.11603 10.3747/co.v17i5.668 10.1111/j.1742-4658.2012.08644.x 10.1016/j.gie.2019.04.232 10.11613/BM.2018.030713 10.1186/s12944-018-0745-1 10.1007/s10654-018-0440-6 10.1007/s10552-011-9831-7 10.1158/1055-9965.EPI-08-1248 10.7326/0003-4819-118-7-199304010-00001 10.1097/CEJ.0000000000000597 10.1080/01635581.2019.1577983 10.1016/j.tem.2019.11.005 10.1016/S0014-5793(03)00261-8 10.1016/S0022-2275(20)33461-1 10.1016/S0021-9150(98)00173-7 10.1161/CIRCULATIONAHA.112.108753 10.1006/bbrc.2000.2877 10.1016/j.ygyno.2009.09.027 10.1002/ijgo.12645 10.1001/jama.2020.0150 10.1186/1476-511X-13-16 10.1007/s10549-009-0594-8 10.1016/j.ygyno.2009.09.034 10.1042/bj3130017 10.1017/S0029665108006976 10.1038/nature07205 10.1093/ajcn/86.3.836S 10.1089/ars.2010.3792
Archives of Gynecology and Obstetrics; Lin Q, Liu W et. al.
Aug 29th, 2021 - The effect of serum lipids on ovarian cancer is controversial. We conducted this study to evaluate the prognostic value of preoperative plasma lipid profile in patients with ovarian cancer. The medical records of 156 epithelial ovarian cancer pati...
International Journal of Epidemiology; Ala-Korpela M, Zhao S et. al.
Aug 19th, 2021 - Quantitative lipoprotein analytics using nuclear magnetic resonance (NMR) spectroscopy is currently commonplace in large-scale studies. One methodology has become widespread and is currently being utilized also in large biobanks. It allows the com...
Journal of Controlled Release : Official Journal of the C... Jin Y, Chifodya K et. al.
Aug 16th, 2021 - The inverse correlation between high-density lipoprotein (HDL) levels in vivo and the risk of Alzheimer's disease (AD) has become an inspiration for HDL-inspired AD therapy, including plain HDL and various intelligent HDL-based drug delivery syste...
Oncology Research and Treatment; Liu MM, Chen ZH et. al.
Aug 12th, 2021 - The prognosis of advanced hepatocellular carcinoma (HCC) varies in patients receiving transcatheter arterial chemoembolization (TACE). In this study, we aimed to assess the prognostic value of serum apolipoprotein B (ApoB)/apolipoprotein A-I (ApoA...
News 9 results
Jul 25th, 2018 - Action Points Two studies of recombinant apolipoprotein A-I (the major HDL apolipoprotein) products failed to show an effect on coronary plaque volume assessed by intravascular ultrasound (IVUS). Note that based on these studies, the development o...
Jan 12th, 2017 - Action Points Baricitinib, an investigational reversible inhibitor of tyrosine kinases JAK 1 and JAK2 signaling, increases the level of serum lipids, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-...
Dec 2nd, 2016 - NEW ORLEANS – The future doesn’t look bright at the moment for use of agents that mimic HDL cholesterol to reverse coronary disease, based on disappointing results of the randomized, phase II MILANO-PILOT trial. Among 120 patients with recent acut.
Aug 14th, 2016 - Action Points Note that this secondary analysis of a clinical trial in patients with rheumatoid arthritis found that decreases in inflammatory markers were associated with improvement in HDL function. While the mechanism is not entirely clear, imp...
Apr 1st, 2011 - CHICAGO – A novel oral drug designed to increase apolipoprotein A-I synthesis and thereby enhance HDL functionality showed mixed results in its first major clinical trial. The 299-patient, 12-week, randomized, double-blind ApoA-I Synthesis Stimula.